Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human TNFRII/CD120b Protein, His Tag, 50µg  

Recombinant human TNFRII/CD120b Protein, His Tag, 50µg

Recombinant Human TNFR2 / CD120b / TNFRSF1B Protein, Leu 23 - Asp 257, expressed in human 293 cells (HEK293), His Tag

Synonym
recombinant, human protein, TNFRSF1B, CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B, TNFR2, TNFR80, p75, p75TNFR

More details

TN2-H5227-050

Availability: within 7 days

364,00 €

Background
TNF RI (also known as the p60 or p55 TNFR) and TNF RII (the p75 or p80 TNFR) are two distinct type I transmembrane glycoproteins that bind TNF with highaffinity. Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Human TNF RII cDNA encodes a 461 amino acid (aa) residue precursor protein with a 22 aa putative signal peptide, a 235 aa extracellular domain, a 20 aa transmembrane domain and a 174 aa cytoplasmic domain. TNFRII is expressed in fetal brain. The protein is produced naturally as a soluble form (sTNFRII). The soluble receptor inhibits TNFα action by competing with cell surface receptors in binding TNFα, thereby blocking its biologic effects. TNFRII is strongly expressed at the cartilage–pannus junction, and plays a major role in a subset of families with multiple cases of rheumatoid arthritis (RA). Further, high plasma levels of sTNFRII were significantly associated with increased incidence of coronary heart disease, independent of established cardiovascular risk factors, and seems to be useful for monitoring the inflammatory activity of sarcoidosis.

Source
Recombinant Human TNFR2, His Tag (TN2-H5227) is expressed from human 293 cells (HEK293). It contains AA Leu 23 - Asp 257 (Accession # AAA36755).
Predicted N-terminus: Leu 23

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.0 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU endotoxin per μg rhTNFRII by the LAL method.

Purity
>95% purity as determined by SDS-PAGE

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "FOXP3+ regulatory T cells are associated with the severity and prognosis of sarcoidosis"
Patterson, Miller, Hancock et al
Front Immunol (2023) 14, 1301991
(2) "Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism"
Anany, Haack, Lang et al
Theranostics (2024) 14 (2), 496-509
(3) "Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization"
Lin, Jiang, Li et al
Theranostics (2024) 14 (2), 662-680
Showing 1-3 of 5780 papers.